Gentamicin ( DrugBank: Gentamicin )

---

3 diseases

ID	Disease name (Link within this page)	Number of trials
36	Epidermolysis bullosa	7
113	Muscular dystrophy	2
299	Cystic fibrosis	1

36. Epidermolysis bullosa

---

Clinical trials : 160 /  Drugs : 195 - (DrugBank : 47) / Drug target genes : 50 - Drug target pathways : 124

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04644627 (ClinicalTrials.gov)	December 1, 2020	20/11/2020	Topical Gentamicin Nonsense Suppression Therapy of EB	TOPICAL GENTAMICIN TREATMENT OF PATIENTS WITH EPIDERMOLYSIS BULLOSA DUE TO NONSENSE MUTATIONS	Epidermolysis Bullosa	Drug: Gentamicin Sulfate	Oslo University Hospital	NULL	Recruiting	N/A	N/A	All	6	Phase 1/Phase 2	Norway
2	EUCTR2020-002337-15-NO (EUCTR)	16/09/2020	29/06/2020	TOPICAL GENTAMICIN TREATMENT OF PATIENTS WITH EPIDERMOLYSIS BULLOSA	TOPICAL GENTAMICIN TREATMENT OF PATIENTS WITH EPIDERMOLYSIS BULLOSA DUE TO NONSENSE MUTATIONS (THE GENTELBULL STUDY) - GENTELBULL	Epidermolysis bullosa caused by nonsense mutations or splice site mutations;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]	Trade Name: Infectogenta Product Name: Gentamicin sulfate 0.1% ointment	Oslo University Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	6	Phase 2	Norway
3	NCT04140786 (ClinicalTrials.gov)	October 31, 2019	23/10/2019	Optimizing IV Gentamicin in JEB	Optimization of Intravenous Gentamicin Treatment to Restore Functional Laminin 332 in JEB Patients With Nonsense Mutations	Junctional Epidermolysis Bullosa	Drug: Gentamicin Sulfate, Injectable	University of Southern California	NULL	Recruiting	N/A	N/A	All	6	Phase 1/Phase 2	United States
4	NCT03392909 (ClinicalTrials.gov)	July 5, 2018	2/1/2018	Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)	Restoration of Full-Length Type VII Collagen in RDEB Patients With Nonsense Mutations After Intravenous Gentamicin Treatment	Recessive Dystrophic Epidermolysis Bullosa	Drug: Gentamicin	University of Southern California	NULL	Recruiting	7 Years	N/A	All	9	Phase 1/Phase 2	United States
5	NCT03526159 (ClinicalTrials.gov)	June 1, 2018	17/4/2018	Gentamicin for Junctional Epidermolysis Bullosa	A Pilot Study of the Restoration of Functional Laminin 332 in JEB Patients With Nonsense Mutations After Topical and Intravenous Gentamicin Treatment	Junctional Epidermolysis Bullosa	Drug: Gentamicin Sulfate	University of Southern California	NULL	Recruiting	N/A	N/A	All	6	Phase 1/Phase 2	United States
6	NCT03012191 (ClinicalTrials.gov)	February 2, 2017	4/1/2017	Gentamicin for RDEB	Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa Patients With Nonsense Mutations	Recessive Dystrophic Epidermolysis Bullosa	Drug: Gentamicin Sulfate	University of Southern California	NULL	Completed	N/A	N/A	All	6	Phase 1/Phase 2	United States
7	NCT02698735 (ClinicalTrials.gov)	February 25, 2016	19/2/2016	Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation Patients		Recessive Dystrophic Epidermolysis Bullosa	Drug: Gentamicin;Drug: Placebo	University of Southern California	NULL	Completed	N/A	N/A	All	5	Phase 1/Phase 2	NULL

Back to top

113. Muscular dystrophy

---

Clinical trials : 622 /  Drugs : 485 - (DrugBank : 99) / Drug target genes : 59 - Drug target pathways : 168

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00451074 (ClinicalTrials.gov)	March 2007	21/3/2007	Six Month Study of Gentamicin in Duchenne Muscular Dystrophy With Stop Codons	A Six Month Randomized, Clinical Trial of Gentamicin in Duchenne Muscular Dystrophy Subjects With Stop Codon Mutations	Duchenne Muscular Dystrophy	Drug: Gentamicin infusions twice a week for six months	Nationwide Children's Hospital	National Institutes of Health (NIH);National Institute of Neurological Disorders and Stroke (NINDS)	Completed	5 Years	20 Years	Male	12	Phase 1	United States
2	NCT00005574 (ClinicalTrials.gov)	February 2000	2/5/2000	Gentamicin Treatment of Muscular Dystrophy	Gentamicin Treatment of Patients With Muscular Dystrophy Due to Nonsense Mutations in Dystrophin	Becker Muscular Dystrophy;Duchenne Muscular Dystrophy	Drug: Gentamicin	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	N/A	N/A	Both	4	Phase 1	United States

299. Cystic fibrosis

---

Clinical trials : 1,696 /  Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00376428 (ClinicalTrials.gov)	January 2003	13/9/2006	Interest of Gentamicin-induced Readthrough in Cystic Fibrosis Patients	Application of Functional Electrophysiological Tests to Evaluate Pharmacological Treatments in Patients With Cystic Fibrosis	Cystic Fibrosis	Drug: Gentamicin	Assistance Publique - Hôpitaux de Paris	NULL	Terminated	N/A	N/A	Both	20	Phase 2	France

Back to top